正在加载图片...
《中癥症泰》2020年第30卷第1期 20 LANFRANCA M P, ZHANG Y, GIRGIS A, et al. Interleukin 22 blinded, randomised controlled phase 2/3 trial [J].Lancet ignaling regulates acinar cell plasticity to promote pancreatic Gastroenterol Hepatol. 2019.4(3): 199-207. tumor development in mice [J]. Gastroenterology, 2019 [35] RENARD E, DANCER P A, PORTAL C, et al. Design of Epub ahead of print bimodal ligands of neurotensin reeeptor I for PET imaging and [21] RAHN S BARBOSA P D MOLLER J L et al. Inflammation fluorescenee-guided surgery of pancreatic eancer [J] associated pancreatic tumorigenesis: upregulation of succinate Chem, 2019. Epub ahead of print dehydrogenase(subunit B)reduces cell growth of pancreatic [36] YUE Y, QIAN W, LI J et al. 2'-hydroxyflavanone inhibit al epithelial cells [J]. Cancers(Basel), 2019, 12(1): E42. the progression of pancreatic cancer cells and sensitizes the 22] LI J. YUAN S NORGARD R J et al. Tumor cell-intrinsic chemosensitivity of EGFR inhibitors via repressing STAT3 USP22 suppresses antitumor immunity in pancreatic caneer signaling [J]. Cancer Lett, 2019. Epub ahead of print [J].Cancer Immunol Res, 2019. Epub ahead of print] [37 FLORIO R VESCHI S DI GIACOMO V et al.The [23 ZHANG Y. XU J HUA J et al. A PD-L2-based immune benzimidazole-based anthelmintic parbendazole: a repurposed drug candidate that synergizes with gemcitabine in pancreatic ductal adenocarcinoma [J]. J Immunother Cancer 2019. 7(1): cancer[J]. Cancers(Basel). 2019. 11(12):E2042 [38 VIVALDI C FORNARO L VASILE E. FOLFIRINOX adjuvant [24] ENGLE DD. TIRIAC H. RIVERA K D, et al. The glycan therapy for pancreatic cancer [J]. N Engl J Med, 2019, CA19-9 promotes pancreatitis and pancreatic cancer in mice 80(12:1187-1188 [J]. Science,2019.3646446:1156-1162 [39] LOF S. KORREL M. VAN HILST J. et al. Impact of neoadjuvant 25] RIQUELME E. ZHANG Y, ZHANG L et al. Tumor microbiome therapy in resected pancreatic ductal adenocarcinoma of the pancreatic body or tail on surgical and oncological outcome:a [J].cl.2019.178(4795-806-12 propensity-score matched multicenter study [J]. Ann Surg [26] AYKUT B. PUSHALKAR S CHEN R, et al. The funga Oncol, 2019. Epub ahead of print mycobiome promotes pancreatic oncogenesis via activation of [40] MACEDO F 1, RYON E, MAITHEL S K, et al. Survival Nare.2019.574077264-267 outcomes associated with clinical and pathological response [27]KNIGHT J C. BAGUNA TORRES J GOLDIN R, et al. Early llowing neoadjuvant FOLFIRINOX or gemcitabine/nab- detection in a mouse model of pancreatic cancer by imaging paclitaxel chemotherapy in resected pancreatic cancer [J] DNA damage response signalling [J].J Nuel Med. 2019 nn surg.2019.2703:400-413 L Epub ahead of print [41] MICHELAKOS T, PERGOLINI I, CASTILLO C F et al 28] VENKAT R. EDIL B H, SCHULICK R D et al. Laparoscopic Predictors of resectability and survival in patients wit ital pancreatectomy is associated with significantly less overall borderline and locally advanced pancreatic cancer who morbidity compared to the open technique: a systematic review underwent neoadjuvant treatment with FOLFIRINOX [J] and meta-analysis [J]. Ann Surg. 2012. 255(6): 1048-1059 rg2019.2694:733- [ 29] RAMIREZ P T, FRUMOVITZ M PAREJA R, et al. Minimally [42] TRUTY M J. KENDRICK M L. NAGORNEY D M,et al. Factors invasive versus abdominal radical hysterectomy for cervical predicting response, perioperative outcomes, and survival cancer[J]. N Engl j Med.2018.37920:1895-1904 following total neoadjuvant therapy for borderline/locally 30] MELAMED A. MARGUL D J. CHEN L, et al. Survival after advanced pancreatic cancer [J]. Ann Surg, 2019. Epub inimally invasive radical hysterectomy for early-stage cervical cancer[J]. N Engl j Med,2018,379020):1905-1914 [43] NGUYEN A M. ZHOU J, SICAIROS B, et al. Upregulation 31] POVES 1. BURDIO F, MORATO O, et al. Comparison of of CD73 confers aequired radioresistance and is required for perioperative outcomes between laparoscopic and open approach maintaining irradiation-selected pancreatic cancer cells in a for pancreatoduodenectomy: the PADULAP randomized mesenchymal state [J]. Mol Cell Proteomics, 2019.[ Epub [32] LIU M, JIS, XU W, et al. Laparoscopic pancreaticoduodenectomy: [44JWANG K. ZHAN Y, HUYNH N, et al. Inhibition of PAKI are the best times coming? [J]. World J Surg Oncol, 2019 suppresses pancreatic cancer by stimulation of anti-tumour 17(1):81 munity through down-regulation of PD-L1 [J].Cancer 33] WANG M, PENG B, LIU J, et al. Practice patterns Lett,2019.[ Epub ahead of print and perioperative outcomes of laparoscopie [45] GOLAN T HAMMEL P. RENI M et al. Maintenance olaparib pancreaticoduodenectomy in China: a retrospective multicenter for germline BRCA-mutated metastatic pancreatic analysis of 1 029 patients [J]. Ann Surg, 2019. Epub ahead N Engl j Med.2019.381(4):317-327 of print [46]NETWORK. NCCN Clinical Practice Guidelines in Oncology 34 VAN HILST J, DE ROOI T BOSSCHA K, et al. Laparoscopi PancreaticAdenocarcinoma[eb/ol].httPs//www.ncen.org. versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient- [47]GOLDSTEIN J B. ZHAO L WANG X, et al.G《中国癌症杂志》2020年第30卷第1期 9 [20] LANFRANCA M P, ZHANG Y, GIRGIS A, et al. Interleukin 22 signaling regulates acinar cell plasticity to promote pancreatic tumor development in mice[J]. Gastroenterology, 2019. [Epub ahead of print] [21] RAHN S, BARBOSA P D, MOLLER J L, et al. Inflammation associated pancreatic tumorigenesis: upregulation of succinate dehydrogenase (subunit B) reduces cell growth of pancreatic ductal epithelial cells[J]. Cancers (Basel), 2019, 12(1): E42. [22] LI J, YUAN S, NORGARD R J, et al. Tumor cell-intrinsic USP22 suppresses antitumor immunity in pancreatic cancer [J]. Cancer Immunol Res, 2019. [Epub ahead of print] [23] ZHANG Y, XU J, HUA J, et al. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma[J]. J Immunother Cancer, 2019, 7(1): 233. [24] ENGLE D D, TIRIAC H, RIVERA K D, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice [J]. Science, 2019, 364(6446): 1156-1162. [25] RIQUELME E, ZHANG Y, ZHANG L, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes [J]. Cell, 2019, 178(4): 795-806. e12. [26] AYKUT B, PUSHALKAR S, CHEN R, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL[J]. Nature, 2019, 574(7777): 264-267. [27] KNIGHT J C, BAGUNA TORRES J, GOLDIN R, et al. Early detection in a mouse model of pancreatic cancer by imaging DNA damage response signalling[J]. J Nucl Med, 2019. [Epub ahead of print] [28] VENKAT R, EDIL B H, SCHULICK R D, et al. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis[J]. Ann Surg, 2012, 255(6): 1048-1059. [29] RAMIREZ P T, FRUMOVITZ M, PAREJA R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer[J]. N Engl J Med, 2018, 379(20): 1895-1904. [30] MELAMED A, MARGUL D J, CHEN L, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer[J]. N Engl J Med, 2018, 379(20): 1905-1914. [31] POVES I, BURDIO F, MORATO O, et al. Comparison of perioperative outcomes between laparoscopic and open approach for pancreatoduodenectomy: the PADULAP randomized controlled trial[J]. Ann Surg, 2018, 268(5): 731-739. [32] LIU M, JI S, XU W, et al. Laparoscopic pancreaticoduodenectomy: are the best times coming?[J]. World J Surg Oncol, 2019, 17(1): 81. [33] WANG M, PENG B, LIU J, et al. Practice patterns a n d p e r i o p e r a t i v e o u t c o m e s o f l a p a r o s c o p i c pancreaticoduodenectomy in China: a retrospective multicenter analysis of 1 029 patients[J]. Ann Surg, 2019. [Epub ahead of print] [34] VAN HILST J, DE ROOIJ T, BOSSCHA K, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient￾blinded, randomised controlled phase 2/3 trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(3): 199-207. [35] RENARD E, DANCER P A, PORTAL C, et al. Design of bimodal ligands of neurotensin receptor 1 for PET imaging and fluorescence-guided surgery of pancreatic cancer[J]. J Med Chem, 2019. [Epub ahead of print] [36] YUE Y, QIAN W, LI J, et al. 2’-hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling[J]. Cancer Lett, 2019. [Epub ahead of print] [37] FLORIO R, VESCHI S, DI GIACOMO V, et al. The benzimidazole-based anthelmintic parbendazole: a repurposed drug candidate that synergizes with gemcitabine in pancreatic cancer[J]. Cancers (Basel), 2019,11(12): E2042. [38] VIVALDI C, FORNARO L, VASILE E. FOLFIRINOX adjuvant therapy for pancreatic cancer[J]. N Engl J Med, 2019, 380(12): 1187-1188. [39] LOF S, KORREL M, VAN HILST J, et al. Impact of neoadjuvant therapy in resected pancreatic ductal adenocarcinoma of the pancreatic body or tail on surgical and oncological outcome: a propensity-score matched multicenter study[J]. Ann Surg Oncol, 2019. [Epub ahead of print] [40] MACEDO F I, RYON E, MAITHEL S K, et al. Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab￾paclitaxel chemotherapy in resected pancreatic cancer[J]. Ann Surg, 2019, 270(3): 400-413. [41] MICHELAKOS T, PERGOLINI I, CASTILLO C F, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX[J]. Ann Surg, 2019, 269(4): 733-740. [42] TRUTY M J, KENDRICK M L, NAGORNEY D M, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer[J]. Ann Surg, 2019. [Epub ahead of print] [43] NGUYEN A M, ZHOU J, SICAIROS B, et al. Upregulation of CD73 confers acquired radioresistance and is required for maintaining irradiation-selected pancreatic cancer cells in a mesenchymal state[J]. Mol Cell Proteomics, 2019. [Epub ahead of print] [44] WANG K, ZHAN Y, HUYNH N, et al. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1[J]. Cancer Lett, 2019. [Epub ahead of print] [45] GOLAN T, HAMMEL P, RENI M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4): 317-327. [46] NETWORK. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma[EB/OL]. https://www.nccn.org, 2020. [47] GOLDSTEIN J B, ZHAO L, WANG X, et al. Germline DNA
<<向上翻页向下翻页>>
©2008-现在 cucdc.com 高等教育资讯网 版权所有